Advances in Immunotherapy for Breast Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Breast Cancer".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 190
Special Issue Editor
Special Issue Information
Dear Colleagues,
The development of immune checkpoint inhibitors (ICIs) has enabled unprecedented breakthroughs in the treatment of both early and advanced cancers. Although ICIs have rapidly become the standard of care for multiple tumor types, a significant proportion of patients do not respond and many develop serious immune-related toxicities. In triple-negative breast cancer, ICIs in combination with chemotherapy have become the standard of care for both early-stage and advanced disease, leading to substantial improvement in tumor responses and survival. Numerous preclinical and clinical studies are ongoing to identify ways to enhance the clinical efficacy of ICIs in breast cancer and minimize toxicities.
For this Special Issue of Current Oncology, we welcome original research and review articles that provide an overview of the latest advances and future challenges in the use of ICIs in the treatment of breast cancer.
Research areas may include (but are not limited to) the following:
- Clinical trials of immunotherapy in breast cancer;
- Immunobiology of breast cancer;
- Translational models of immunotherapy for breast cancer;
- Strategies to overcome immunotherapy resistance;
- Biomarkers for patient selection;
- Managing immunotherapy toxicities;
- Real-world data on the clinical efficacy and toxicity of ICIs in breast cancer.
I look forward to receiving your contributions to this Special Issue.
Dr. Rossanna C. Pezo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- immune checkpoint inhibitors
- breast cancer
- immunotherapy resistance
- biomarkers
- PD-1
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Recent advances in immunotherapy for hormone receptor positive breast cancer
Authors: Jose P. Leone; Elge Werneck Araujo Junior
Affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215, USA
